The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers of Protein Handling/Autophagy, Exosomes and Lipid, 2019Measuring Lipids in iPSC-derived Dopamine Neurons to Identify Parkinson’s Biomarkers
Study Rationale:
Changes in lipid metabolism have been strongly associated with Parkinson’s disease (PD). Lipids have the potential to be important biomarkers for PD, but the lack of appropriate tools... -
Research Grant, 2019Biologically Meaningful Modulation of Alpha-synuclein Expression via Clenbuterol
Promising Outcomes of Original Grant:
The drug clenbuterol, a beta-2 adrenoreceptor agonist, has been shown to decrease alpha-synuclein expression and to be neuroprotective in some models. Our results... -
Alpha-synculein Biology and Therapies, 2018Effects of Post-translational Modifications on Alpha-synuclein Aggregation
Study Rationale:
Evidence suggests that the protein alpha-synuclein can cause the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or aggregates) on the... -
Improved Biomarkers and Clinical Outcome Measures, 2019GBA Sequencing and Detection of Mutations, Deletions, Insertions and Recombinations with the GBA Pseudo Gene
Study Rationale:
Mutations in the GBA gene are the most common genetic cause of Parkinson’s disease. This gene has a nearby pseudogene, which is a genetic material that is very similar to the original... -
Alpha-synculein Biology and Therapies, 2019Chaperones of Alpha-synuclein for Membrane Fusion Involved in Synaptic Transmission
Study Rationale:
Abnormal accumulation of the protein alpha-synuclein is a pathological hallmark of Parkinson’s disease (PD). We and others have evidence that aggregated alpha-synuclein could harm... -
LRRK2 LEAPS, 2018Link between LRRK2, Alpha-synuclein and Lysosomal Function Supplement
Study Rationale:
Our goal is to test whether people with Parkinson’s disease (PD) who carry a LRRK2 mutation (compared to those carrying another genetic PD-predisposing mutation or people with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.